Patient preferences for pharmacogenetic screening in depression

International Journal of Technology Assessment in Health Care

Volumn 24, Issue 1, 2008, Pages 96-103

  Herbild, Louise ^a,b,c   Gyrd Hansen, Dorte ^a,b,c   Bech, Mickael ^b  

^a Danish Institute of Health Services Research

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c Dansk Sundhedsinstitut   (Denmark)

Author keywords

Depressive disorder; Genetic; Healthcare economics and organizations; Pharmacogenetics; Polymorphism

Indexed keywords

DIAGNOSIS; DISEASES; GENETIC ENGINEERING; POLYMORPHISM;

DEPRESSIVE DISORDER; HEALTHCARE ECONOMICS; PHARMACOGENETIC SCREENING; PHARMACOGENETICS;

PATIENT MONITORING;

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; GENETIC POLYMORPHISM; GENETIC SCREENING; HEALTH CARE COST; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; QUESTIONNAIRE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DENMARK; DEPRESSION; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PATIENT SATISFACTION; PHARMACOGENETICS; QUESTIONNAIRES;

EID: 38549150774     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462307080129     Document Type: Article

References (44)

1. Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005;78:559-581.
2. Berto P, D'Ilario D, Ruffo P, et al. Depression: Cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ. 2000;3:3-10.
3. Biosam. Farmakogenetik i Danmark. Biosam. 2003;15.
4. Bridges JF. Stated preference methods in health care evaluation: An emerging methodological paradigm in health economics. Appl Health Econ Health Policy. 2003;2:213-224.
5. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Econ. 1997;6:327-340.
6. Brook O, van Hout H, Nieuwenhuyse H, Heerdink E. Impact of coaching by community pharmacists on drug attitude of depressive primary care patients and acceptability to patients; a randomized controlled trial. Eur Neuropsychopharmacol. 2003;13:1-9.
7. Brøsen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004;59:5-12.
8. Brøsen K. Klassisk Farmakogenetik. Ugeskr Læger. 2005;167:2143-2146.
9. Caraco Y. Genes and the response to drugs. N Engl J Med. 2004;351:2867-2869.
10. Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000;20:246-251.
11. Cuijpers P, Smit F, Oostenbrink J, et al. Economic costs of minor depression: A population-based study. Acta Psychiatr Scand 2007;115:229-236.
12. Danmarks Statistik. Befolkningens brug af internet 2007. 42nd ed. Danmarks Statistik; 2007.
13. Efron B, Tibshirani RJ. Introduction to the bootstrap. 1st ed. London: Chapman & Hall/CRC; 1993.
14. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. Depression: A neglected major illness. J Clin Psychiatry. 1993;54:419-424.
15. Heller T, Kirchheiner J, Armstrong VW, et al. AmpliChip CYP450 GeneChip: A new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit. 2006;28:673-677.
16. Hensher D, Rose JM, Greene WH. Applied choice analysis - A primer. 1st ed. Cambridge: Cambridge University Press; 2005.
17. Herbild L. Working paper: Designing a DCE to outlay patients' and the publics' preferences for genetic screening in the treatment of depression. 2007:1 ed. University of Southern Denmark, Institute of Public Health - Health Economics; 2007.
18. Hole AR. A comparison of approaches to estimating confidence intervals for willingness to pay measures. Health Econ. 2007;16:827-840.
19. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6-13.
20. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol. 2005;207(Suppl):52-56.
21. Ingelman-Sundberg M. Email correspondence: Preferences for genetic screening for CYP-polymorphisms. 2007.
22. Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: Implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci. 2005;360:1563-1570.
23. Kirchheiner J, Bertilsson L, Bruus H, et al. Individualized medicine-implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry. 2003;36(Suppl 3):S235-S243.
24. Kirchheiner J, Brøsen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages. Acta Psychiatrica Scand. 2001;104:173-192.
25. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473.
26. Kolonien Filadelfia. Laboratoriet i Dianalund. Kolonien Filadelfia Laboratoriet 2007 August 9. Available at: URL: http://www.laboratoriet. epilepsihospitalet.dk/.
27. Kuhfeld WF. Marketing research methods in SAS experimental design, choice, Conjoint and graphical techniques. TS-722 ed. SAS Institute; 2005.
28. Luppa M, Heinrich S, Angermeyer MC, et al. Cost-of-illness studies of depression A systematic review. J Affect Disord. 2007;98:29-43.
29. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391-396.
30. Matchar DB, Thakur ME, Grossman I, et al. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). 146 ed. Durham, NC: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services: Duke Evidence-based Practice Center; 2006.
31. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry. 1990;51(Suppl):60-69.
32. Mors NPO, Børglum AD. Status og perspektiver inden for psykiatrisk genomisk medicin. Ugeskr Læger. 2005;167:2191-2193.
33. Mortensen PB. Depressioners epidemiologi [The epidemiology of depression]. In: DSI Institut for Sundhedsvæsen, editor. Depression - en folkesygdom der skal behandles? København: DSI Institut for Sundhedsvæsen; 1999:59-66.
34. Mulder H, Herder A, Wilmink FW, et al. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol Drug Saf. 2006;15:107-114.
35. Rasmussen JO, Christensen M, Svendsen JM, et al. CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand J Clin Lab Invest. 2006;66:129-136.
36. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: Impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin Pharmacol Ther. 2004;75:386-393.
37. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65:341-347.
38. Smith RD, Olsen JA, Harris A. A review of methodological issues in the conduct of willingness-to-pay studies in health care I: Construction and specification of the contingent market. working paper 84 ed. Australia: Centre for Health Program Evaluation, Monash University; 1999.
39. Sobocki P, Ekman M, Agren H, et al. The mission is remission: Health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract. 2006;60:791-798.
40. Sobocki P, Lekander I, Borgstrom F, et al. The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry. 2007;22:146-152.
41. Suh DC. Consumers' willingness to pay for pharmacy services that reduce risk of medication-related problems. J Am Pharm Assoc (Wash). 2000;40:818-827.
42. Unützer J, Katon WJ, Russo J, et al. Willingness to pay for depression treatment in primary care. Psychiatr Serv. 2003;54:340-345.
43. Wedlund PJ, de Leon J. Cytochrome P450 2D6 and antidepressant toxicity and response: What is the evidence? Clin Pharmacol Ther. 2004;75:373-375.
44. Wittchen H, Jacobi F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;15:357-376.